Bone microstructural and BMD changes during the progressive stage in NAFLD were related to IGF-1 and IGFBP-1 levels, which reduces the mRNA expressions of Runx and OSX, resulting in decreased osteoblast function (at 32 weeks). This evidence concerns the gene IGFBP1 and metabolic dysfunction-associated steatotic liver disease.